{"entity":{"id":"oncotherapy-solutions","kind":"company","name":"Oncotherapy Solutions","aka":["Oncotherapy Solutions, LLC"],"tldr":"Oncotherapy Solutions is a Seattle company developing peptide drug conjugates: small peptides that carry a cell-killing drug to tumour cells. Its lead, OTS-P22, is being prepared for triple-negative breast cancer.","summary":"Oncotherapy Solutions, LLC develops peptide drug conjugates and bispecific drug conjugates for drug-resistant and metastatic solid tumours. Its most advanced preclinical candidate, OTS-P22, targets a receptor that the company says is highly expressed in many solid tumours; the company reports that a single intravenous dose inhibited tumour growth in an HCC1806 triple-negative breast cancer mouse model, and plans IND-enabling studies for triple-negative breast, metastatic ovarian and endometrial cancers. A 2026 National Cancer Institute SBIR award funds a lead peptide drug conjugate for triple-negative breast cancer; its abstract describes conjugates aimed at the luteinising hormone-releasing hormone receptor.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://oncotherapysolutions.com/"},{"label":"Pipeline","url":"https://oncotherapysolutions.com/pipeline"},{"label":"NIH RePORTER: award 1R43CA306418-01A1","url":"https://reporter.nih.gov/project-details/11402095"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":["adcs","targeted-therapy"],"technologies":["peptide-drug-conjugate"],"targets":[],"drugs":["ots-p22"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website (home and pipeline pages) and the NIH RePORTER record read on 4 November 2026. The website does not name the receptor OTS-P22 targets; the award abstract describes LHRH receptor conjugates, and whether OTS-P22 is one of them is not stated."],"hq":"Seattle, WA","country":"US","companyType":"biotech","website":"https://oncotherapysolutions.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":400000,"source":"https://reporter.nih.gov/project-details/11402095","note":"NCI SBIR (R43) award 1R43CA306418-01A1: Stable, highly potent and safe lead peptide drug conjugate for the treatment of triple-negative breast cancer"}]},"route":"/companies/oncotherapy-solutions/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"peptide-drug-conjugate","kind":"technology","name":"Peptide-drug & small-molecule-drug conjugates","route":"/technologies/peptide-drug-conjugate/"}],"drug":[{"id":"ots-p22","kind":"drug","name":"OTS-P22","route":"/drugs/ots-p22/"}]}}